A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT06827236 by BioNTech SE, with 380 participants planned, started 2025-04-23 and due to reach its primary completion in 2029-08. Interventions recorded: BNT323 and BNT327.